WO1998048782A1 - Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe - Google Patents
Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe Download PDFInfo
- Publication number
- WO1998048782A1 WO1998048782A1 PCT/DE1998/000979 DE9800979W WO9848782A1 WO 1998048782 A1 WO1998048782 A1 WO 1998048782A1 DE 9800979 W DE9800979 W DE 9800979W WO 9848782 A1 WO9848782 A1 WO 9848782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- release
- compressed
- active
- active substance
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a process for the production of peroral applicable solid pharmaceutical forms with controlled release of active substance, with at least three out of four compresses containing an active substance or a combination of active substances being variable in their selection and number and to be solid according to known processes which can be managed with little expenditure of equipment and time Pharmaceutical forms are processed.
- This process produces oral solid medicinal forms that implement the most diverse pharmaceutically required release profiles of active ingredients or combinations of active ingredients, such as delayed, evenly sustained or one adapted to specific rhythms (pulsatile) release.
- the release profile below is the release ( Delivery) of the active ingredient or combination of active ingredients to be understood from the pharmaceutical form depending on the time
- the aim in pharmaceutical technology is to find processes for converting a pharmaceutical active substance into a pharmaceutical form which, among other things, ensures that the active substance is released according to therapy after application
- mini tablets are used as filling in capsules. Mini tablets require special pressing tools and place very high demands on the recipe. NÜRNBERG, E. and SURMANN, P. (ed.) Also point in HAG_ERS HANDBUCH, vol. 2 -METHODEN, 5th completely, reworked. On. , Springer Verlag Berlin, Heidelberg, New York, 1 991, p. 1 123, with regard to the gastric passage time - due to the respective dosage form - to the clear differences between the monolithic 'single unit' forms and the 'multiple unit''Shapes.
- the quantities controlling the release of active substance are based in most cases on osmotic processes, on a diffusion process and / or erosion process.
- DI LUCCI O, R.C. et al. , 'Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers', J. Pharm. Be. , 83 (1994) p. 104-106 describe the controlled drug release from drug forms in the form of a delayed release of the drug theophylline by using a mixture of polyvinyl alcohol (PVA) and a polyvinyl alcohol-methyl acrylate copolymer (PVA-MA) with low crystallinity. While PVA alone leads to quick-release tablets, PVA-MA enables delayed release of the active ingredient, depending on the proportion. It has been found that a PVA: PVA-MA mixture of 1: 9: 10 causes the desired delayed release of the active ingredient, so that the tablets achieved a bioavailability of almost 80% in a test on dogs.
- PVA polyvinyl alcohol
- PVA-MA polyvinyl alcohol-
- 373-376 show the delayed release of theophylline based on the combination of different polyacrylates that are mixed Place a barrier (mixed barrier) around the dosage form and lead to a matrix diffusion-controlled release of the active ingredient.
- the dosage forms contain 50% theophylline, Carbopol ® 974P as a retarding additive, spray-dried lactose and 0.5% lubricant. With this principle, only two of the usual release profiles could be realized, a release of the 0th order - drug release is largely linear, ie the same amount of drug is released in the same time interval - and a release proportional to the square root of the time.
- JU NG I NG ER, HE, 'Oral Applications of Pulsatile Drug Delivery' describes in: Gurny, R., Junginger, HE, Peppas, NA (ed.), Pulsatile Drug Delivery, Ed. 1,ticianliche Verlagsgesellschaft mbH, Stuttgart, 1 993, p. 1 1 3-1 34, several systems for achieving pulsatile release profiles of drug delivery, such as coated tablets, pellets or microspheres, OROS ® , PULS I NCAP ® ; time-controlled explosion systems, special layered tablets.
- Patent DE 44 43 1 75 A1 shows a pulsatile pharmaceutical form, the release of which is adapted to the episodes of illness or pain.
- the patent specification EP 0 71 9 555 A2 describes the use of melonin for the production of oral pulsatile pharmaceutical forms.
- the proposed pulsatile pharmaceutical form is a capsule. This contains the active ingredient embedded in various carriers. However, no compresses have been specifically defined that release the active ingredient in specific proportions. Furthermore, this pulsatile pharmaceutical form is not claimed for combinations of active substances.
- the invention has for its object to provide a method for producing orally applicable solid drug forms with controlled release of active ingredient, any pharmaceutically required release profile can be realized and the drug forms are produced with little equipment and time.
- the object is achieved according to the invention in that at least three out of four compresses containing an active ingredient or combination of active ingredients, the number and number of which can be varied, are mixed, granulated, tableted and / or tabletted by known methods with pharmaceutically acceptable auxiliaries and / or carriers. or coated so that any pharmaceutically required release profile of the active ingredient or combination of active ingredients is generated.
- a first compressed product A of the four compressed products provides a quick-release active ingredient delivery, the compressed product delivering at least 75% of its active ingredient content within 45 minutes.
- Another compressed B realizes release of active substance according to a uniformly sustained release profile, whereby the compressed releases 100% of its active substance content at the earliest after 3 hours after a release profile of approximately 0th order.
- the drug delivery should be largely linear, that is, in the same time interval delivered the same amounts of active ingredient.
- Such release profiles of the active ingredient or combination of active ingredients can be achieved, inter alia, with hydrophilic matrix tablets, diffusion-controlled lacquer coatings or lipophilic matrix tablets.
- a third compressed C realizes a delayed release of the active ingredient. With a pH of 6-7.5 corresponding to the conditions in the duodenum and intestine, this compressed product releases at least 75% of its active ingredient content within 45 minutes.
- Such a release profile of the active ingredient can usually be achieved by coating a rapid-release tablet analogously to Compressed A with an enteric coating, for example based on polymethacrylate or shellac.
- the compressed D realizes a release profile of the active substance or a combination of active substances, which combines retarding moments with uniformly sustained moments.
- the compressed product releases 100% of its active substance content at the earliest after a further 3 according to a release profile of approximately 0th order. Release profiles that combine retarding moments with evenly sustained moments can be achieved with enteric coated hydrophilic matrix tablets or combinations of enteric coated with diffusion controlled varnish coatings.
- the capsule produced by this process has the advantages of a multiple unit form.
- Figure 1 shows the release profile of the active ingredients based on the compressions A to D as a model.
- the level of other endogenous hormones follows a pronounced circadian rhythm, i.e. their concentration in the blood changes over the course of 24 hours.
- these hormones are: prednisone, prednisone ion, cortexon, corticosterone, cortisol and aldosterone.
- melatonin is predominantly secreted during the night.
- the blood level of analogues or inhibitors of these hormones can also be subject to a circadian rhythm.
- Exemplary substance classes are: antidiabetics, glucocorticoids, mineralocorticoids, antihistamines.
- Hormonal active ingredients can also be used in combinations. It may be necessary to apply each hormonal agent either with its own release profile or together in one release profile. Examples of such combinations of hormonal active ingredients can be: progesterone / estradiol, testosterone / progesterone, progesterone / estriol, progesterone / estrone, cortisol / aldosterone.
- solid pharmaceutical forms which can be used orally are produced, which implement all conceivable pharmaceutically required release profiles of active substances or combinations of active substances and whose production is possible with a few easily controllable technological processes and with little expenditure on equipment and time.
- the invention is illustrated by the following examples.
- Progesterone - becomes fast in an initial dose of 10 mg, - afterwards evenly sustained and
- Estradiol - is released quickly.
- Progesterone, estradiol, lactose, corn starch and hydroxypropyl methyl cellulose are mixed and with a solution of the PVP in ethanol
- the granules are dried, mixed with talc and magnesium stearate and to a tablet of the specified
- the coating is applied to the tablets in a suitable device using a dispersion of Eudragit, talc and triethyl citrate and dried.
- the compressed products thus produced are placed in a capsule.
- Each active ingredient component with its own release profile is applied. There is a rapid release of active ingredient by means of compressed A - 10 mg progesterone and 1.6 mg estradiol after 0.25 h -, by means of compressed C a delayed release of active ingredient - 10 mg progesterone after 2.5 h - and by means of compressed D an active ingredient release , which combines the delayed moments with evenly sustained moments - 30 mg progesterone after 6 h.
- Melatonin, lactose, corn starch and hydroxypropylmethyl cellulose are mixed and granulated with a solution of the PVP in ethanol 96%.
- the granules are dried, mixed with talc and magnesium stearate and pressed into a tablet of the specified diameter and the specified mass.
- the coating is applied to the tablets in a suitable device using a dispersion of Eudragit, talc, glycerol triacetate and anti-foam emulsion and dried.
- the compressed products thus produced are placed in a capsule.
- Figure 3 in conjunction with Table 2 shows the release profile of the active ingredient melatonin as a function of the quantitative release over time.
- Hydrocortisone, lactose, corn starch and hydroxypropylmethyl cellulose are mixed and neutralized with a solution of the PVP in ethanol 96%.
- the granules are dried, mixed with talc and magnesium stearate and pressed into a tablet of the specified diameter and the specified mass.
- the coating is applied to the tablets in a suitable device using a dispersion of Eudragit, talc, glycerol triacetate and anti-foam emulsion and dried.
- the compressed products thus produced are placed in a capsule.
- Figure 4 in conjunction with Table 3 show the release profile of the active ingredient hydrocortisone as a function of the quantitative cumulative release over time.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE59812485T DE59812485D1 (de) | 1997-04-29 | 1998-04-07 | Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe |
DK98928152T DK0979069T3 (da) | 1997-04-29 | 1998-04-07 | Fremgangsmåde til fremstilling af peroralt anvendelige faste lægemiddelformer med styret afgivelse af aktivt stof |
JP54646998A JP2002511849A (ja) | 1997-04-29 | 1998-04-07 | 制御された作用物質引渡し量を有する経口的に使用可能な固体の調剤形の製造法 |
AT98928152T ATE286723T1 (de) | 1997-04-29 | 1998-04-07 | Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe |
BR9809328-2A BR9809328A (pt) | 1997-04-29 | 1998-04-07 | Processo para preparação de formas sólidas de medicamentos empregáveis peroralmente com desprendimento controlado de substância ativa |
AU80099/98A AU8009998A (en) | 1997-04-29 | 1998-04-07 | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance |
PL336572A PL191692B1 (pl) | 1997-04-29 | 1998-04-07 | Sposób wytwarzania doustnych, stałych produktów farmaceutycznych z regulowanym wydzielaniem substancji czynnej |
SK1479-99A SK147999A3 (en) | 1997-04-29 | 1998-04-07 | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance |
CA002290017A CA2290017C (en) | 1997-04-29 | 1998-04-07 | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance |
EP98928152A EP0979069B1 (de) | 1997-04-29 | 1998-04-07 | Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe |
HU0003121A HU226670B1 (en) | 1997-04-29 | 1998-04-07 | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance |
UA99116416A UA49952C2 (uk) | 1997-04-29 | 1998-07-04 | Спосіб виготовлення твердих медикаментозних форм з регульованою віддачею ефективної речовини для перорального застосування та тверда медикаментозна форма |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19718012.4 | 1997-04-29 | ||
DE19718012A DE19718012C1 (de) | 1997-04-29 | 1997-04-29 | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998048782A1 true WO1998048782A1 (de) | 1998-11-05 |
Family
ID=7828056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/000979 WO1998048782A1 (de) | 1997-04-29 | 1998-04-07 | Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe |
Country Status (19)
Country | Link |
---|---|
US (1) | US6117450A (de) |
EP (1) | EP0979069B1 (de) |
JP (1) | JP2002511849A (de) |
AR (1) | AR010414A1 (de) |
AT (1) | ATE286723T1 (de) |
AU (1) | AU8009998A (de) |
BR (1) | BR9809328A (de) |
CA (1) | CA2290017C (de) |
CO (1) | CO5070636A1 (de) |
CZ (1) | CZ300174B6 (de) |
DE (2) | DE19718012C1 (de) |
ES (1) | ES2236908T3 (de) |
HU (1) | HU226670B1 (de) |
PL (1) | PL191692B1 (de) |
PT (1) | PT979069E (de) |
RU (1) | RU2193396C2 (de) |
SK (1) | SK147999A3 (de) |
UA (1) | UA49952C2 (de) |
WO (1) | WO1998048782A1 (de) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775599A1 (fr) * | 1998-03-09 | 1999-09-10 | Besins Iscovesco Lab | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
JP2003523378A (ja) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | 治療剤製品、その使用及び製剤形態 |
JP2003523372A (ja) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | 抗生物質及び抗真菌剤組成物 |
JP2003531115A (ja) * | 2000-02-24 | 2003-10-21 | アドバンシス ファーマシューティカル コーポレイション | インヒビターを有する抗生物質組成物 |
JP2004523510A (ja) * | 2001-01-12 | 2004-08-05 | サン・ファーマシューティカル・インダストリーズ・リミテッド | スペーストドラッグデリバリーシステム |
JP2005526059A (ja) * | 2002-03-07 | 2005-09-02 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質組成物 |
WO2005102271A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for glucocorticoid replacement therapy |
JP2006500344A (ja) * | 2002-08-02 | 2006-01-05 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法およびその作成方法 |
JP2006528185A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2006528189A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
JP2006528190A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2006528699A (ja) * | 2003-05-19 | 2006-12-21 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質組成物 |
JP2007502294A (ja) * | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007504141A (ja) * | 2003-08-29 | 2007-03-01 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007513869A (ja) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
WO2010115615A1 (en) * | 2009-04-07 | 2010-10-14 | Duocort Pharma Ab | Improved glucocorticoid therapy |
US9066869B2 (en) | 1998-12-17 | 2015-06-30 | Purdue Pharma | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US9925139B2 (en) | 2004-04-22 | 2018-03-27 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
GB0007419D0 (en) † | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
EP1377276B1 (de) * | 2001-04-10 | 2011-10-05 | Sun Pharma Advanced Research Company Limited | Zubereitung zur getakteten freisetzung |
AU2007202779B2 (en) * | 2001-08-15 | 2008-08-07 | University Of Sheffield | Delayed and sustained drug release |
GB0119848D0 (en) * | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
WO2004108067A2 (en) * | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
GB0817120D0 (en) * | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
US9375437B2 (en) * | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312927A1 (en) * | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
CN105412016B (zh) * | 2010-10-27 | 2019-01-22 | 上海宣泰医药科技有限公司 | 一种含番茄红素、白藜芦醇或褪黑素的肠溶固体制剂及其制备方法 |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
MX2017016823A (es) | 2015-06-22 | 2018-03-12 | Lipocine Inc | Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2749745A1 (de) * | 1977-09-15 | 1979-03-29 | Heyden Chem Fab | Nitrofurantoin-retard-praeparat zur oralen verabfolgung und verfahren zu seiner herstellung |
WO1992000730A1 (en) * | 1990-07-13 | 1992-01-23 | Farcon Ag | A controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs |
WO1992010173A1 (en) * | 1990-12-05 | 1992-06-25 | Smithkline Beecham Corporation | Pharmaceutical compositions |
EP0548595A2 (de) * | 1991-12-12 | 1993-06-30 | Bayer S.p.A. | Pharmazeutisches System zur Verabreichung von therapeutisch wirksamen Dihydropyridinen mit gesteuerter Freisetzung, und Herstellungsverfahren |
EP0722732A1 (de) * | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Pyrimidindionderivate enthaltendes Arzneimittel mit verlängerter Wirkstoffabgabe |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2749749A1 (de) * | 1977-11-07 | 1979-05-10 | Sumitomo Chemical Co | Verfahren zur herstellung von 5-carboxy-2-acetylthiophen |
DE2836355A1 (de) * | 1978-08-19 | 1980-02-28 | Boehringer Sohn Ingelheim | Neue mexiletin-retardform |
IT1101649B (it) * | 1978-12-15 | 1985-10-07 | Lehner Ag | Composizione farmaceutica ad azione prolungata contenente acidi biliari |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
DE4443175A1 (de) * | 1994-12-05 | 1996-06-13 | Jenapharm Gmbh | Neue pulsatile Arzneiform |
DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
EP0951278A2 (de) * | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Minitablette formulierung zur verzögerte freigabe von cisapride |
-
1997
- 1997-04-29 DE DE19718012A patent/DE19718012C1/de not_active Expired - Lifetime
-
1998
- 1998-04-07 PL PL336572A patent/PL191692B1/pl not_active IP Right Cessation
- 1998-04-07 AT AT98928152T patent/ATE286723T1/de not_active IP Right Cessation
- 1998-04-07 JP JP54646998A patent/JP2002511849A/ja active Pending
- 1998-04-07 PT PT98928152T patent/PT979069E/pt unknown
- 1998-04-07 CA CA002290017A patent/CA2290017C/en not_active Expired - Fee Related
- 1998-04-07 WO PCT/DE1998/000979 patent/WO1998048782A1/de active IP Right Grant
- 1998-04-07 HU HU0003121A patent/HU226670B1/hu not_active IP Right Cessation
- 1998-04-07 CZ CZ0380499A patent/CZ300174B6/cs not_active IP Right Cessation
- 1998-04-07 EP EP98928152A patent/EP0979069B1/de not_active Expired - Lifetime
- 1998-04-07 DE DE59812485T patent/DE59812485D1/de not_active Expired - Lifetime
- 1998-04-07 AU AU80099/98A patent/AU8009998A/en not_active Abandoned
- 1998-04-07 BR BR9809328-2A patent/BR9809328A/pt not_active Application Discontinuation
- 1998-04-07 SK SK1479-99A patent/SK147999A3/sk unknown
- 1998-04-07 RU RU99125113/14A patent/RU2193396C2/ru not_active IP Right Cessation
- 1998-04-07 ES ES98928152T patent/ES2236908T3/es not_active Expired - Lifetime
- 1998-04-24 US US09/065,863 patent/US6117450A/en not_active Expired - Fee Related
- 1998-04-29 CO CO98023494A patent/CO5070636A1/es unknown
- 1998-04-29 AR ARP980101982A patent/AR010414A1/es not_active Application Discontinuation
- 1998-07-04 UA UA99116416A patent/UA49952C2/uk unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2749745A1 (de) * | 1977-09-15 | 1979-03-29 | Heyden Chem Fab | Nitrofurantoin-retard-praeparat zur oralen verabfolgung und verfahren zu seiner herstellung |
WO1992000730A1 (en) * | 1990-07-13 | 1992-01-23 | Farcon Ag | A controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs |
WO1992010173A1 (en) * | 1990-12-05 | 1992-06-25 | Smithkline Beecham Corporation | Pharmaceutical compositions |
EP0548595A2 (de) * | 1991-12-12 | 1993-06-30 | Bayer S.p.A. | Pharmazeutisches System zur Verabreichung von therapeutisch wirksamen Dihydropyridinen mit gesteuerter Freisetzung, und Herstellungsverfahren |
EP0722732A1 (de) * | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Pyrimidindionderivate enthaltendes Arzneimittel mit verlängerter Wirkstoffabgabe |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656929B1 (en) | 1998-03-09 | 2003-12-02 | Laboratoires Besins Iscovesco | Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process |
WO1999045932A1 (fr) * | 1998-03-09 | 1999-09-16 | Laboratoires Besins Iscovesco | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
FR2775599A1 (fr) * | 1998-03-09 | 1999-09-10 | Besins Iscovesco Lab | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
US10022330B2 (en) | 1998-12-17 | 2018-07-17 | Rhodes Pharmaceuticals L.P. | Methods of preparing oral controlled release formulations |
US9949931B2 (en) | 1998-12-17 | 2018-04-24 | Rhodes Pharmaceuticals L.P. | Methods of treating attention deficit hyperactivity disorder |
US9066869B2 (en) | 1998-12-17 | 2015-06-30 | Purdue Pharma | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US9801823B2 (en) | 1998-12-17 | 2017-10-31 | Rhodes Pharmaceuticals L.P. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US10039719B2 (en) | 1998-12-17 | 2018-08-07 | Rhodes Pharmaceuticals L.P. | Methods of treating attention deficit hyperactivity disorder |
US10463624B2 (en) | 1998-12-17 | 2019-11-05 | Rhodes Pharmaceuticals L.P. | Controlled release formulations |
JP2003523378A (ja) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | 治療剤製品、その使用及び製剤形態 |
JP2012001528A (ja) * | 2000-02-24 | 2012-01-05 | Victory Pharma Inc | 治療剤製品、その使用及び製剤形態 |
JP2003531115A (ja) * | 2000-02-24 | 2003-10-21 | アドバンシス ファーマシューティカル コーポレイション | インヒビターを有する抗生物質組成物 |
JP2003523372A (ja) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | 抗生物質及び抗真菌剤組成物 |
JP2004523510A (ja) * | 2001-01-12 | 2004-08-05 | サン・ファーマシューティカル・インダストリーズ・リミテッド | スペーストドラッグデリバリーシステム |
JP2005526059A (ja) * | 2002-03-07 | 2005-09-02 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質組成物 |
JP2006500344A (ja) * | 2002-08-02 | 2006-01-05 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法およびその作成方法 |
JP2006528699A (ja) * | 2003-05-19 | 2006-12-21 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質組成物 |
JP2006528185A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2006528189A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
JP2006528190A (ja) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007502294A (ja) * | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007504141A (ja) * | 2003-08-29 | 2007-03-01 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007513869A (ja) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
CN1942176B (zh) * | 2004-04-22 | 2013-09-18 | 杜奥科特药物公司 | 用于糖皮质激素替代疗法的药物组合物 |
EP3072507A1 (de) * | 2004-04-22 | 2016-09-28 | DuoCort Pharma AB | Pharmazeutische zusammensetzungen für glucocorticoid-ersatztherapie |
US9925139B2 (en) | 2004-04-22 | 2018-03-27 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
WO2005102271A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for glucocorticoid replacement therapy |
US10583146B2 (en) | 2004-04-22 | 2020-03-10 | Shire Viropharma Incorporated | Pharmaceutical compositions for glucocorticoid replacement therapy |
US8425937B2 (en) | 2004-04-22 | 2013-04-23 | Duocort Pharma Ab | Pharmaceutical compositions for glucocorticoid replacement therapy |
WO2005102271A3 (en) * | 2004-04-22 | 2006-08-03 | Duocort Ab | Pharmaceutical compositions for glucocorticoid replacement therapy |
WO2010115615A1 (en) * | 2009-04-07 | 2010-10-14 | Duocort Pharma Ab | Improved glucocorticoid therapy |
US10111839B2 (en) | 2014-10-31 | 2018-10-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10292938B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10449159B2 (en) | 2014-10-31 | 2019-10-22 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10292939B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10500162B2 (en) | 2014-10-31 | 2019-12-10 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10507186B2 (en) | 2014-10-31 | 2019-12-17 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512613B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512612B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10568841B2 (en) | 2014-10-31 | 2020-02-25 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10688060B2 (en) | 2014-10-31 | 2020-06-23 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896722B2 (en) | 2014-10-31 | 2024-02-13 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Also Published As
Publication number | Publication date |
---|---|
CZ380499A3 (cs) | 2000-04-12 |
PL191692B1 (pl) | 2006-06-30 |
UA49952C2 (uk) | 2002-10-15 |
EP0979069B1 (de) | 2005-01-12 |
HU226670B1 (en) | 2009-06-29 |
ES2236908T3 (es) | 2005-07-16 |
HUP0003121A3 (en) | 2001-03-28 |
DE19718012C1 (de) | 1998-10-08 |
JP2002511849A (ja) | 2002-04-16 |
SK147999A3 (en) | 2000-07-11 |
HUP0003121A2 (hu) | 2001-02-28 |
AR010414A1 (es) | 2000-06-07 |
BR9809328A (pt) | 2000-07-04 |
PT979069E (pt) | 2005-05-31 |
RU2193396C2 (ru) | 2002-11-27 |
CZ300174B6 (cs) | 2009-03-04 |
PL336572A1 (en) | 2000-07-03 |
ATE286723T1 (de) | 2005-01-15 |
US6117450A (en) | 2000-09-12 |
EP0979069A1 (de) | 2000-02-16 |
AU8009998A (en) | 1998-11-24 |
CA2290017C (en) | 2004-06-29 |
CO5070636A1 (es) | 2001-08-28 |
DE59812485D1 (de) | 2005-02-17 |
CA2290017A1 (en) | 1998-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0979069A1 (de) | Verfahren zur herstellung peroral anwendbarer fester arzneiformen mit gesteuerter wirkstoffabgabe | |
DE69429826T3 (de) | Opioid-formulierungen zur schmerzbehandlung | |
DE69723303T2 (de) | Arzneimittel mit verzögerter wirkstoffabgabe | |
DE69910604T2 (de) | Neue kügelchen mit kontrollierter freisetzung, ein verfahren zu deren herstellung und diese enthaltende formulierung des typs "multiple unit" | |
EP0642788A2 (de) | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreitsetzung | |
EP0163000A2 (de) | Pharmazeutisches Produkt in Form von Pellets mit kontinuierlicher, verzögerter Wirkstoffabgabe | |
WO1998004249A2 (de) | Tramadol multiple unit formulierungen | |
WO2000078289A1 (de) | Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac | |
DE60022332T2 (de) | Ketoprofen- mikrogranulat, verfahren zur herstellung desselben sowie pharmazeutsche zusammensetzungen | |
DE3856555T2 (de) | Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption | |
DE3814532A1 (de) | Dhp-retard-zubereitung | |
DE69817848T2 (de) | Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus | |
EP0994696B1 (de) | Kontrolliert freisetzende pharmazeutische zubereitung mit einem ace-hemmer als wirkstoff | |
DE102004043863A1 (de) | Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum | |
DE4229820C2 (de) | Pharmazeutische Zubereitung auf Gestagen-Basis | |
DE2343218A1 (de) | Zubereitungsformen von n-(2-furfuryl)4-chlor-5-sulfamoylanthranilsaeure und verfahren zu ihrer herstellung | |
EP0719555A2 (de) | Verwendung von Melatonin zur Herstellung peroraler pulsatiler Arzneiformen | |
DE60312642T2 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
DE102008053044B4 (de) | Phosphatbinder und ihre Verwendung | |
DE2260384C3 (de) | Oral zu applizierendes Corticosteroid-Präparat | |
DE69925491T2 (de) | Pharmazeutische zusammensetzung enthaltend beclomethason-dipropionat zur behandlung entzündlicher darmerkrankungen | |
WO2009135623A1 (de) | Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung | |
EP1075253A2 (de) | Wirkstoff enthaltende orale oder mucosale zubereitung mit steuerbarer wirkstofffreisetzung und ihre verwendung | |
MXPA99009337A (en) | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance | |
DE3941703C2 (de) | Bumetanid enthaltende pharmazeutische Zubereitung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/009337 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998928152 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-3804 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2290017 Country of ref document: CA Ref country code: CA Ref document number: 2290017 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 147999 Country of ref document: SK |
|
WWP | Wipo information: published in national office |
Ref document number: 1998928152 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-3804 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998928152 Country of ref document: EP |